Latest Breaking News On - Follicular lymphoma - Page 12 : comparemela.com

Kymriah Elicits Long-Lasting Responses in R/R Follicular Lymphoma

Researchers reported long-lasting responses and no new safety concerns in patients with relapsed/refractory follicular lymphoma during the 2023 ASH Annual Meeting and Exposition.

United statesStephenj schusterDrug administrationAmerican society of hematologyAnnual meetingMargarita louis dreyfus professorPenn medicineFollicular lymphoma

Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL

Odronextamab produced durable responses and a generally manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Sabarish ram ayyappanRegeneron pharmaceuticalsEuropean organization for research of cancerCity of hope cancer treatment centerRam ayyappanHope cancer treatment centerEuropean organizationAnn arborPrescription drug user fee actDiffuse largeb cell lymphomaFollicular lymphomaPrespecified analysisPivotal phasePatients with relapsed refractory diffuse largeb cell lymphomaElm 2 trial

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoTammy allenVesna tosicNantes university hospitalEuropean medicines agencyEuropean unionAmerican society of hematologyRegeneron genetics centerNantes universityRegeneron pharmaceuticals incEuropean organization for researchOdronextamab clinical programExchange commissionDrug administrationAmerican society

Latest Odronextamab Data in Relapsed/Refractory Follicular

Latest Odronextamab Data in Relapsed/Refractory Follicular
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoTammy allenExchange commissionOdronextamab clinical programAmerican society of hematologyNantes university hospitalDrug administrationRegeneron genetics centerNantes universityEuropean unionEuropean organization for researchRegeneron pharmaceuticals incEuropean medicines agencyAmerican societyAnnual meeting

Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.

Niravn shahCollege of wisconsinMedical collegeAnn arborNash meetingFollicular lymphomaPhase 1 2 bruin trial nct03740529